Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06688656
- Locations
- 🇨🇳
241, West Huaihai Road, Shanghai, Shanghai, Shanghai, China
A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer
- Conditions
- Advanced Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- BeBetter Med Inc
- Target Recruit Count
- 120
- Registration Number
- NCT06685796
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
- Conditions
- Non Squamous Non Small Cell Lung Cancer
- Interventions
- Drug: EU-sourced Keytruda®Drug: US-sourced Keytruda®
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- mAbxience Research S.L.
- Target Recruit Count
- 726
- Registration Number
- NCT06687369
- Locations
- 🇬🇪
Site 108002, Tbilisi, Georgia
🇷🇸Site 121005, Užice, Serbia
🇯🇵Site 207002, Hakodate-shi, Japan
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: Toripalimab/Tirelizumab
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 320
- Registration Number
- NCT06682780
- Locations
- 🇨🇳
FuDan University Shanghai Cancer Center, Shanghai, Shanghai, China
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
- Conditions
- Unresectable Locally Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
- Target Recruit Count
- 380
- Registration Number
- NCT06682611
Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
- Conditions
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Target Recruit Count
- 142
- Registration Number
- NCT06663098
- Locations
- 🇮🇹
Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy
🇮🇹IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
🇮🇹IRCCS Azienda Ospedaliero_Universitaria di Bologna, Bologna, Italy
Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06659042
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
- Conditions
- Stage III NSCLC
- Interventions
- Radiation: Curative hypofractionated radiotherapy
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
- Target Recruit Count
- 152
- Registration Number
- NCT06656598
- Locations
- 🇫🇷
Caen - CHU, Caen, France
🇫🇷Caen - CRLCC, Caen, France
🇫🇷Créteil - CHI, Créteil, France
A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.
- Conditions
- Solid Tumor CancerChemotherapy Induced NeutropeniaG-CSF
- Interventions
- Drug: carboplatin/cisplatin-etoposideDrug: TP regimenDrug: Cisplatin/pemetrexed or Carboplatin/pemetrexed
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 200
- Registration Number
- NCT06649448
- Locations
- 🇨🇳
Shandong Cancer Hospital and Institute, Jinan, Shandong, China
Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Radiation: Radiotherapy 60 Gray/dayRadiation: Radiotherapy 66 Gray/dayRadiation: Radiotherapy 70 Gray/day
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Target Recruit Count
- 355
- Registration Number
- NCT06647563
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.